Stock Market Reviews

LIMN (Liminatus Pharma, Inc.) News

Get the latest news, insights, and market updates on LIMN (Liminatus Pharma, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation
  LA PALMA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a clinical-stage immuno-oncology company developing next-generation CD47-blockade therapies, announced today that it has entered into a Memorandum of Understanding (MOU) with Capital Trust Group Limited (CTG), a New Zealand-based investment management firm, for a USD 30,000,000 equity financing via an earn-out mechanism to support Liminatus’s research and development of advanced immunotherapy assets. Subje
  Oct 30, 2025 - $LIMN
• BNB Falls Below $750 as Crypto Market Sell-Off Erases Corporate-Fueled Optimism
  The drop came amid a market sell-off triggered by bitcoin's drop to $112,800, which sparked $360 million in liquidations in 24 hours.
  Aug 5, 2025 - $LIMN
• Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies
  Strategic Internal Review initiated for treasury diversification through a prospective digital asset subsidiary — no entity formed, no capital committedLA PALMA, Calif., July 25, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies, today announced that its Board of Directors and executive team have formally initiated a strategic review to explore the potential formation of a
  Jul 25, 2025 - $LIMN
• Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy
  Agreement with Digital Offering Advances Company's plan to assess innovative treasury-backed financing pathsLA PALMA, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies, today announced it has entered into an engagement agreement with Digital Offering LLC, a FINRA- and SEC-registered broker-dealer, to serve as its exclusive placement agent in connection with
  Jul 24, 2025 - $LIMN
• Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy
  Preclinical-stage biotech company explores digital asset treasury opportunities to enhance capital efficiency while maintaining core focus on immunotherapy innovationLA PALMA, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies, today announced that it has initiated a strategic review to evaluate the potential inclusion of regulated digital asset strategies a
  Jul 22, 2025 - $LIMN